| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board
Telomir also announces Board of Directors departures and additions
TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available.
Telomir's Board of Directors has named Erez Aminov, currently Chairman of the Board and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), as a director, Chairman of the Board and Chief Executive Officer of Telomir.
